Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for depression and perioperative neuropsychiatric disorders in elderly patients with malignant tumors
ChiCTR2300069249Phase 3Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of esketamine in perioperative neurocognitive disorder, postoperative delirium (POD) and major depressive disorder (MDD) (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: Incidence of postoperative delirium, Neuropsychological testing and 1 more. Started Feb 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
perioperative neurocognitive disorderpostoperative delirium (POD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2300069249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069249.